First-order effects

• Wojcicki's 23andMe now has a public balance sheet and roughly $600M of new capital to fund its push beyond ancestry kits into therapeutics.
• Branson's SPAC vehicle completes its purpose — taking 23andMe public at a $3.5B valuation — with sponsors capturing the spread between the headline valuation and the cash actually delivered.

Second-order effects

• The successful listing keeps the SPAC door open for other consumer-data companies — Near followed within a year, going public via a SPAC merger at a ~$1B valuation on claims of 1.6B anonymized profiles.
• Public-market scrutiny now attaches directly to 23andMe's core question: whether a genetics database can be monetized fast enough to justify the price, since kit sales alone did not get it here.

Third-order effects

• The pattern that follows is brutal repricing for SPAC-era listings: 23andMe's stock went on to a 98% crash from its $6B peak, Wojcicki sought to take the company private, and by 2025 the company filed for bankruptcy with Wojcicki stepping down — a template for how quickly consumer-data valuations can unwind when the subscription-and-drug-discovery pivot stalls.
• Genetic databases end up treated less as durable moats than as assets to be sold or restructured, sharpening the privacy questions that surface whenever a bankrupt genomics company's data changes hands.